How the Accountability Gap is Reshaping CDMO Selection Beyond Manufacturing Capacity

Cell and gene therapy (CGT) manufacturing has always required coordination beyond the manufacturing suite itself. Long before material reaches production, activities are already underway across clinical sites, collection centers, logistics networks, quality teams, and sponsor organizations. Each group contributes to the successful execution of the therapy manufacturing process, yet no single organization controls every part of the journey from beginning to end.

For years, this reality was treated as an operational challenge that experienced teams simply learned to navigate. Manufacturing schedules were built with contingencies in mind, and institutional knowledge helped to bridge the gaps between functions. Complexity existed, but was typically manageable because the scale of operations allowed people to keep the greater operational workflow moving along by force of will and a deep understanding of how individual pieces fit together. 

As therapies advance toward later-stage development and commercial operations, that approach becomes increasingly difficult to sustain. Larger patient populations, broader geographic reach, and expanding networks of partners introduce additional dependencies at nearly every stage of the process. Manufacturing remains central to success, but manufacturing performance is becoming more closely tied to activities that take place outside the direct control of the manufacturing organization.

This shift has created a growing accountability gap across the industry. Contract development and manufacturing organizations (CDMOs) remain responsible for delivering predictable outcomes and maintaining production schedules while supporting sponsor timelines, even though many of the variables most likely to influence those outcomes originate elsewhere. What once felt like an operational reality has become a strategic consideration, particularly as sponsors place greater emphasis on scalability and long-term program readiness, oftentimes in direct response to shifting investor and regulator expectations. 

Accountability Extends Far Beyond Manufacturing

Manufacturing is often discussed as though it exists at the center of the development process. In practice, however, manufacturing is one part of a much larger, end-to-end supply chain. 

The successful execution of CGT manufacturing depends on a chain of events that begins well before material enters production and continues long after it leaves. For the end-to-end workflow to function as intended, collection activities must occur on time and as planned. Materials need to arrive according to expected timelines and specifications, often functioning within a “just in time” framework. Documentation must be complete and audit-ready at all times, and the various quality reviews, transport activities, sample management, and operational handoffs all contribute to the final outcome.

The challenge is that responsibility for these activities is typically distributed across multiple organizations, while accountability frequently remains concentrated. Sponsors ultimately need predictable execution, and patients depend on this reliability. When disruptions occur, attention naturally turns to understanding how they will affect manufacturing schedules and milestone achievements, and ultimately overall program progress. 

This dynamic places CDMOs in a unique position. They operate within an ecosystem that they do not fully control, yet they are often expected to absorb the impact of variability wherever it originates. Operational leaders understand this reality well. An issue upstream may have little to do with manufacturing itself, but manufacturing still becomes responsible for managing the consequences that follow. 

This doesn’t mean that accountability has been incorrectly assigned. Cell and gene therapy programs depend on organizations that can bring structure and predictability to a highly complex environment. The challenge is that the scope of that responsibility continues to expand. 

Scale Amplifies Operational Dependencies

Many advanced therapy programs can accommodate a surprising amount of variability during early development. When teams are smaller, communication is easier, and problems can often be resolved through direct interaction between stakeholders. Experience and institutional knowledge frequently compensate for the gaps that are far more difficult to manage in larger operating environments. But as programs grow, those informal mechanisms become harder to rely upon. 

Additional trial sites, for example, create new coordination requirements. New geographies will introduce new regulatory, logistical, and operational complexities. And growing patient populations will naturally increase the volume of materials moving through the workflow. Each expansion creates new pressure points and handoffs where information and materials will need to move successfully between organizations. 

The resulting challenge is often described as a question of scale, but scale itself is rarely the issue. Most organizations, after all, expect that volumes will increase as a program progresses. What becomes more difficult is maintaining consistency as the number of interdependencies continues to grow. 

And the effect is cumulative. Each additional handoff or localized workaround introduces another opportunity for delays or resource constraints to influence the broader program. Any one of these events may seem manageable in isolation, but as the operating environment grows more complex, their collective impact becomes far more significant. 

This is one reason why accountability gaps tend to become more visible as therapies mature. The larger the supporting ecosystem becomes, the greater the distance between operational responsibility and direct operational control. 

Sponsor Expectations are Evolving Alongside the Industry

The way sponsors evaluate manufacturing partners has evolved considerably over the past decade. Expertise and technical capabilities (plus available capacity, of course) are still essential considerations that will continue to play a central role in manufacturing partner selection. But at the same time, sponsors are placing greater emphasis on understanding how organizations perform within increasingly complex operating environments. 

Part of this shift reflects a growing recognition that operational performance extends beyond what can be measured through traditional manufacturing metrics alone. Delays, deviations, and missed milestones remain important indicators, but they often represent the visible outcome of challenges that have been building behind-the-scenes for weeks or months. 

Long before a disruption becomes visible, teams invest effort in keeping programs on track. Quality groups investigate exceptions as operational teams adjust schedules, and the client-facing teams manage client communications and expectations as resources are redirected to address emerging issues. Much of this activity never appears on a performance report, but it plays a meaningful role in determining if execution ultimately remains on track. 

As therapies advance through larger clinical studies and toward commercialization, sponsors are paying closer attention to the conditions that make consistency possible. Questions that once centered primarily on manufacturing capabilities increasingly extend into broader areas of operational performance. Sponsors want insight into how CDMOs coordinate across stakeholders, how they respond when conditions change, and what they do to maintain continuity as programs become more complex. 

This shift reflects broader changes across the CGT landscape. Clinical networks are expanding and supply chains are becoming more sophisticated. Commercial readiness conversations are beginning earlier, and investors and regulators alike are expecting a higher degree of operational maturity than was common during earlier phases of industry growth. 

As a result, sponsors are assessing whether potential partners can support more than the immediate manufacturing need. They are evaluating whether the broader operating model can support future complexity without requiring significant restructuring at each stage of growth, and in this environment, predictability becomes both a reflection of organizational capability and an increasingly important measure of partnership quality. 

Creating Greater Continuity Across the CGT Ecosystem

As sponsors place greater emphasis on predictable execution, attention naturally shifts toward the operating environment surrounding manufacturing.

A highly capable manufacturing operation still depends on timely material arrivals, documentation continuity, aligned quality processes, inventory visibility, and reliable coordination across numerous stakeholders. When those activities become fragmented across disconnected systems and providers, maintaining consistency often requires substantial effort from both sponsors and CDMOs.

This is one reason many organizations are looking more closely at supply chain continuity as a contributor to manufacturing performance.

For CDMOs, bridging the gap between accountability and control doesn’t mean owning every individual part of the process. Instead, it requires a supporting ecosystem around manufacturing that is intentionally designed to reduce fragmentation and create more coordinated execution. 

Cryoport Systems’ end-to-end supply chain platform was built around that need for continuity. By bringing together cryopreservation, biostorage, logistics, clinical sample management, secondary packaging and labeling, and regulatory support within a unified ecosystem, Cryoport Systems helps reduce the operational disconnects that can emerge as programs scale. Consistent quality processes across the global footprint and fewer handoffs between providers support a more predictable operating environment for both CDMOs and sponsors. 

As therapies progress from early development through pivotal studies and commercialization, that continuity is becoming increasingly valuable. Complexity will never be removed from advanced therapies. But it’s possible to create an operating model capable of supporting that complexity without allowing it to compromise execution. 

Reliability is a Competitive Advantage

The accountability gap is unlikely to disappear. Advanced therapies will continue to rely on interconnected supply chains that require specialized expertise and carefully coordinated execution across multiple stakeholders. 

What’s changing is the degree to which reliability influences partnership decisions. As sponsors evaluate manufacturing partners through a broader operational lens, the ability to maintain continuity across the wider environment surrounding manufacturing is becoming increasingly important. 

For CDMOs, that shift presents an opportunity. Organizations that can combine manufacturing excellence with strong operational alignment will be better positioned to protect schedules and support sponsor confidence, ultimately delivering more consistent outcomes as therapies continue to scale.